probably a good spot for a ST trade IMO of course. Does Leerink know something? Anyone see the report?
It's all of the above and everyone knows the GILD competition is very strong. JNJ/ACHN are hoping they can steal 20% market share, that would be a huge cash flow win for ACHN. To get there, the data will have to be excellent.
They are still in the early/mid stage, so they might need to optimize the combo or triplet before they get to near 100% and fewer weeks of treatment (don't expect a miracle). It will be a win at this stage if JNJ keeps the research going/moves forward and a cash milestone would also be great.
it was a downgrade. Until we see the report we don't know the reason. Maybe they were paid to help the shorts escape. maybe they heard something, maybe they looked at the chart, impossible to know the reason behind the decision.
bad data =$4 good date =$8-9, really good, 100% and short duration $10+ One potential issue is with only 20 patients per arm, each patient =5%, so of just 1-2 are not responding it would make the numbers look not so great.
Nothing is going to happen until we get through the next round of clinical trial info. Relax, or sell, but don't cheapen the company by sending stupid letters...
I did this while holding a large position in IMGN. I got no response from any buyers, the BOD members were a complete waste of time. At least the ARNA BOD fired Jack, that's more than I can say for most. They should have done it years ago, but better late than when it's too late.
interesting divergence today (oil vs. stock price), maybe the market is expecting some M&A to start happening.
that's crazy talk, all that transparency. How do you expect the financial criminals to stay in business? They will have to go back to the illegal drug trade, or shaking people down, or some other illegal mob-like activities.
Sad and hard to believe. This company could easily be worth 10x if any one of the 3 pipeline products works well. We all hate to be patient, but there doesn't seem to be any other choice, the financial criminals will not allow the price to rise and without significant new demand, they are in control.
patience, ARNA is a biotech value stock. Maybe the BVF fund will invest soon, or Baker Bros. That would be helpful.
yes, both the IBB and XBI are getting killed
ACHN are totally focused now on the development Factor D. The JNJ Hep C drugs are currently valued by the market at about $1-2/sh and ACHN will not know the trial results until published. JNJ is in control and owns the drugs now. There's a fair amount of upside, but at this point/price not a lot of downside, maybe to $4-5.
when are they due to report? For the past several quarters the stock has dropped 7-10% on the date of the announcement because they have failed to meet expectations regarding cost reductions. I hope they get it right this time!!! Under performing today is not a good sign. I do think they made exactly the right call regarding the div.
people don't always update their Linked-in bios right away. Either way it's not a big deal except they do need to be cutting costs and not paying for high cost educational programs for people that are doing jobs way above their level of experience and competency.
I believe she's attending U of Chicago's very expensive MBA program. I just don't know if ARNA is paying or not.